TME

BostonGene and Prisma Health Announce Collaboration Aimed at Predicting Efficacy of Immunotherapy in Rare Cancers

Retrieved on: 
torsdag, januari 18, 2024
Research, Pharmaceutical, Oncology, Technology, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Cardiology, Biotechnology, Health, Tumor microenvironment, Neoplasm, Patient, Prisma, MD, Multimedia, Cancer, Glomus tumor, Prisma Health, Gene expression, TME

View the full release here: https://www.businesswire.com/news/home/20240118823602/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240118823602/en/
    In collaboration with Prisma Health’s Rare Tumor Center, BostonGene will analyze tissue and peripheral blood from rare cancer solid-tumor patients to understand the molecular underpinnings of immune-activating drugs commonly used to enhance a person's innate mechanisms to fight cancer.
  • BostonGene will perform detailed analyses of primary tumors and immunoprofiling of matched peripheral blood collected during this cohort of the trial, which is currently enrolling patients.
  • Prisma Health, the largest healthcare system in South Carolina, established its Rare Tumor Center in 2014 with a focus on improved outcomes for patients with rare cancers.
  • The center is part of the Prisma Health Cancer Institute, which actively participates in more than 300 clinical trials annually.

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
fredag, januari 26, 2024
Neoplasm, Carcinoma, Therapy, Flare, ADC, UC, Biotechnology, Knowledge, ASCO, PPARG, Cancer, Factorization of polynomials, PD, Human, Safety, Biomarker, TME, Pharmacokinetics

CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced a poster presentation outlining the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG, at the 2024 ASCO Genitourinary Cancers Symposium taking place from January 25-27, 2024 in San Francisco, CA.

Key Points: 
  • "FlareTx has built a robust body of preclinical evidence that supports investigation of FX-909 in clinical trials in patients," said Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of Flare Therapeutics. "
  • Results shown to date reveal that FX-909 eradicates tumors in urothelial cancer (UC) animal models at low oral doses.
  • Exploratory objectives include the evaluation of patient selection biomarkers from tissue and blood samples and association with clinical outcomes.
  • In the US, approximately 10 sites are planned for Phase 1A and 12-15 sites for Phase 1B.

TME Chart 2023 Year-End Charts Officially Unveiled, Featuring Notable Artists including Joker Xue, Zhou Shen and Tia Ray

Retrieved on: 
fredag, januari 26, 2024
Dark, Streamflow, Tencent Music, Music, Tristesse, Meet Yourself, Uni, Multimedia, Chart, Female, Male, Attention, Environment, Suzume, Christmas Star, Human, TME, Growth

SHENZHEN, China, Jan. 25, 2024 /PRNewswire/ -- TME Chart, one of the brand of Tencent Music Entertainment Group, officially released the TME Chart 2023 Year-End Charts on January 23rd, featuring three main categories: General Chart, Uni Chart, and Wave Chart.

Key Points: 
  • SHENZHEN, China, Jan. 25, 2024 /PRNewswire/ -- TME Chart, one of the brand of Tencent Music Entertainment Group, officially released the TME Chart 2023 Year-End Charts on January 23rd, featuring three main categories: General Chart, Uni Chart, and Wave Chart.
  • A major overhaul characterized the 2023 Year-End Charts, sponsored by JD Supermarket, to present the TME Chart Year-End Chart special series.
  • Furthermore, TME Chart 2023 Year-End Charts combine the comprehensive results from both the Uni Chart and Wave Chart to select and present the Top 10 Songs and Top 10 Artists of the year.
  • The Top 10 Artists showcase prominent figures such as Zhou Shen, Zhang Bichen, Dao Lang, Joker Xue, and Tia Ray.

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

Retrieved on: 
tisdag, januari 16, 2024
Mortality, Neoplasm, Patient, CD163, JAK1, Therapy, Research, Survival, Cancer, CD86, TGF-B2, OTCQB, STAT1, APC, HR, CD14, TGFB2, Interferon gamma, Messenger, TME, DMG, Glioma, Vaccine

We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

Key Points: 
  • We hope that sharing these findings from our research team will contribute to the eradication of cancer," stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
  • IFNGR2 is a critical component of the IFN-γ signaling pathway, playing a significant role in mediating the immune system's defense against cancer.
  • The expression levels of IFNGR2 and TGFB2 (1.51-fold increase (p = 0.002) and 1.58-fold increase (p = 5.5 × 10−4), respectively) were significantly upregulated in pbDMG tumors compared with normal brainstem/pons samples.
  • Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients.

Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Drug Candidate in CIVO Phase 0 Clinical Trial

Retrieved on: 
tisdag, januari 16, 2024
Tumor microenvironment, Patient, Overalls, Partnership, Nissan Presage, GMP, Food, Drug development, CIVO, FDA, Doctor of Philosophy, TME, Vaccine

The drug candidate, PBA-0405, is owned by Poland-based biopharmaceutical company, Pure Biologics, and represents the earliest stage material to date that will be evaluated in patients in a CIVO Phase 0 clinical trial.

Key Points: 
  • The drug candidate, PBA-0405, is owned by Poland-based biopharmaceutical company, Pure Biologics, and represents the earliest stage material to date that will be evaluated in patients in a CIVO Phase 0 clinical trial.
  • PBA-0405 is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
  • "We are very excited by this first opportunity to evaluate pre-GMP material in partnership with Pure Biologics," said Patrick Gray, PhD, Presage CEO.
  • "Our partnership with Presage was key in achieving this milestone and we eagerly await the first insights into drug efficacy and impact on the tumor microenvironment."

Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies

Retrieved on: 
torsdag, januari 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Genetics, Tumor microenvironment, AVATAR, CGMP, Education minister, Good manufacturing practice, TME, Mountaineering, Gene editing, Pharmaceutical industry

Xcell Biosciences, Inc. (Xcellbio), a platform technology company focused on cell and gene therapy applications, today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies.

Key Points: 
  • Xcell Biosciences, Inc. (Xcellbio), a platform technology company focused on cell and gene therapy applications, today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies.
  • As part of this collaboration, ElevateBio becomes the first member of Xcellbio’s beta program for its new AVATAR Foundry™ device.
  • In addition, Michael Paglia, Chief Technology Officer at ElevateBio’s BaseCamp®, has joined Xcellbio’s Scientific Advisory Board.
  • ElevateBio is a technology-driven company commercializing its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate the development of genetic medicines.

Tencent Music Entertainment Group and Universal Music Group Extend Multi-year Strategic Licensing Agreement

Retrieved on: 
onsdag, januari 3, 2024
Atmos, Music, Ecosystem, Family, Partnership, TME, Tencent Music, HKEX, QQ Music, HD, UMG, Growth, Creativity, EVP, Universal Music Group

SHENZHEN, China, Jan. 3, 2024 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, and Universal Music Group ("UMG"), the world's leading music-based entertainment company, today announced the renewal of a multi-year strategic licensing agreement, fortifying their shared commitment to creating value for artists and exceptional experiences for music lovers.

Key Points: 
  • SHENZHEN, China, Jan. 3, 2024 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, and Universal Music Group ("UMG"), the world's leading music-based entertainment company, today announced the renewal of a multi-year strategic licensing agreement, fortifying their shared commitment to creating value for artists and exceptional experiences for music lovers.
  • Under the agreement, TME continues to have access to UMG's music catalogue for QQ Music, Kugou Music, Kuwo Music, and WeSing.
  • Adam Granite, UMG's EVP of Market Development, said, "We are pleased to extend our licensing agreement with TME for the Chinese market.
  • UMG will continue to work with TME to bring the very best in music to these passionate music consumers, and to explore new ways to enhance their listening experiences."

VinBrain to Launch AI-centric Solutions to Save Lives and Advance Precision Care at RSNA 2023

Retrieved on: 
måndag, december 4, 2023
Cloud, Liver, Radiology, Microsoft Band, Life expectancy, Stanford University, Cancer, Vingroup, Diagnosis, Microsoft, Hepatocellular carcinoma, Artificial intelligence, SOTA, EDS, Privacy, Exhibition, Knowledge, Fellow, Azure, Health care, Scientific Reports, Medical imaging, Physician, Tuberculosis, HCC, CXR, AI, TACE, HIPAA, Patient, Medicine, NVIDIA, TB, TME, HIS, Learning, Research, R&D, RIS, PACS, EMR, NIST, Health, Graphics processing unit, RSNA, Medical device

Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.

Key Points: 
  • Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.
  • Expediting interoperability and streamlining, DrAid Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care.
  • Dr. Michael C. Muelly, medical partner of VinBrain shared his point of view about clinical practices and values of the solutions during product launch at RSNA 2023.
  • At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid for Tuberculosis Screening (CXR Screening).

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

Retrieved on: 
onsdag, november 29, 2023
Immunotherapy, Daiichi Sankyo, TNF, Neoplasm, Tumor microenvironment, TME, HER2, Woman, Breast cancer, TAM, Disease, Interferon gamma, MUC4, Poster, ADC, Vaccine

Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.

Key Points: 
  • Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.
  • “This work demonstrates another way that MUC4 expression causes resistance to HER2-targeted immunotherapy in women with resistant breast cancer," said Dr. Schillaci, who is also associated with CONICET and is senior author of this work.
  • INB03 decreases MUC4 expression on the surface of the breast cancer cells increasing the ability of the antibody to bind to the HER2 target on the cancer cell.
  • Resistance to trastuzumab immunotherapy can be predicted prospectively based on simple immunohistochemistry stains detecting tumor expression of MUC4.

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

Retrieved on: 
tisdag, november 28, 2023
VISTA, Cancer, Associate, Professor, Oncology, Patient, Tumor microenvironment, TME, KOL, Pharmaceutical industry

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors.

Key Points: 
  • SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors.
  • Details are as follows:
    The event will feature presentations from two key opinion leaders in immuno-oncology:
    Michael A. Curran, Ph.D., Associate Professor at MD Anderson Cancer Center Department of Immunology, who will discuss key challenges with current cancer therapies and the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment (TME) and drive anti-tumor activity.
  • Evan Y. Yu, M.D., Professor and Medical Oncology Section Head at Fred Hutchinson Cancer Center, who will join Kineta leadership to discuss immuno-oncology clinical trials and review the new positive monotherapy data from the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors.
  • A live question and answer session will follow the formal presentations.